RT Journal Article
SR Electronic
T1 Global disparities in SARS-CoV-2 genomic surveillance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.21.21262393
DO 10.1101/2021.08.21.21262393
A1 Brito, Anderson F.
A1 Semenova, Elizaveta
A1 Dudas, Gytis
A1 Hassler, Gabriel W.
A1 Kalinich, Chaney C.
A1 Kraemer, Moritz U.G.
A1 Ho, Joses
A1 Tegally, Houriiyah
A1 Githinji, George
A1 Agoti, Charles N.
A1 Matkin, Lucy E.
A1 Whittaker, Charles
A1 ,
A1 ,
A1 ,
A1 ,
A1 Howden, Benjamin P
A1 Sintchenko, Vitali
A1 Zuckerman, Neta S.
A1 Mor, Orna
A1 Blankenship, Heather M
A1 Oliveira, Tulio de
A1 Lin, Raymond T. P.
A1 Siqueira, Marilda Mendonça
A1 Resende, Paola Cristina
A1 Vasconcelos, Ana Tereza R.
A1 Spilki, Fernando R.
A1 Aguiar, Renato Santana
A1 Alexiev, Ivailo
A1 Ivanov, Ivan N.
A1 Philipova, Ivva
A1 Carrington, Christine V. F.
A1 Sahadeo, Nikita S. D.
A1 Gurry, Céline
A1 Maurer-Stroh, Sebastian
A1 Naidoo, Dhamari
A1 von Eije, Karin J
A1 Perkins, Mark D.
A1 Kerkhove, Maria van
A1 Hill, Sarah C.
A1 Sabino, Ester C.
A1 Pybus, Oliver G.
A1 Dye, Christopher
A1 Bhatt, Samir
A1 Flaxman, Seth
A1 Suchard, Marc A.
A1 Grubaugh, Nathan D.
A1 Baele, Guy
A1 Faria, Nuno R.
YR 2021
UL http://medrxiv.org/content/early/2021/12/09/2021.08.21.21262393.abstract
AB Genomic sequencing provides critical information to track the evolution and spread of SARS-CoV-2, optimize molecular tests, treatments and vaccines, and guide public health responses. To investigate the spatiotemporal heterogeneity in the global SARS-CoV-2 genomic surveillance, we estimated the impact of sequencing intensity and turnaround times (TAT) on variant detection in 167 countries. Most countries submit genomes >21 days after sample collection, and 77% of low and middle income countries sequenced <0.5% of their cases. We found that sequencing at least 0.5% of the cases, with a TAT <21 days, could be a benchmark for SARS-CoV-2 genomic surveillance efforts. Socioeconomic inequalities substantially impact our ability to quickly detect SARS-CoV-2 variants, and undermine the global pandemic preparedness.One-Sentence Summary Socioeconomic inequalities impacted the SARS-CoV-2 genomic surveillance, and undermined the global pandemic preparedness.Competing Interest StatementNDG is an infectious diseases consultant for Tempus Labs and the National Basketball Association. MAS receives grants and contracts from the National Institutes of Health, the US Food & Drug Administration, the US Department of Veterans Affairs and Janssen Research & Development. OGP has undertaken work for AstraZeneca on SARS-CoV-2 classification and genetic lineage nomenclature.Funding StatementES and SF acknowledges the EPSRC (EP/V002910/1). GB acknowledges support from the Internal Fondsen KU Leuven/Internal Funds KU Leuven (Grant No. C14/18/094) and the Research Foundation - Flanders (Fonds voor Wetenschappelijk Onderzoek - Vlaanderen, G0E1420N, G098321N). GWH acknowledges support from NIH F31 AI154824. MAS acknowledges support from grants NIH R01 AI153044 and NIH U19 AI135995. MUGK acknowledges funding from the Oxford Martin School, EUH2020 project MOOD, Branco Weiss Fellowship and grants from The Rockefeller Foundation and Google.org. NDG acknowledges support from Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University and CDC Contract # 75D30120C09570. OGP acknowledges support from the Oxford Martin School. NRF acknowledges support by a Wellcome Trust and Royal Society Sir Henry Dale Fellowship (204311/Z/16/Z). NRF and ECS acknowledge support by a Medical Research Council-Sao Paulo Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0) (http://caddecentre.org/) and by Bill & Melinda Gates Foundation (INV-034540 and INV-034652). Rede Corona-omica BR MCTI/FINEP is affiliated to RedeVirus/MCTI (awards FINEP = 01.20.0029.000462/20, CNPq = 404096/2020-4). CCK acknowledges support from the US Public Health Service Ruth L. Kirschstein National Research Service Award (5T35HL007649-35). RSA acknowledges funding from CNPq: 312688/2017-2 and 439119/2018-9; MEC/CAPES: 14/2020 - 23072.211119/2020-10; FINEP: 0494/20 01.20.0026.00 and UFMG-NB3 1139/20 and FAPERJ: 202.922/2018.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study can be found in this GitHub repository: https://github.com/andersonbrito/paper_2021_metasurveillance